NEW AMBRX BIOPHARMA INC (AMAM) Stock Price, Quote, News and Overview
NASDAQ:AMAM - Nasdaq - US6418711080 - Common Stock - Currency: USD
AMAM Quote, Performance and Key Statistics
28
+0.02 (+0.07%)
The current stock price of AMAM is 28 USD. In the past month the price increased by 0.79%. In the past year, price increased by 188.96%.
AMAM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.21 | 330.30B | ||
| AMGN | AMGEN INC | 13.9 | 155.11B | ||
| GILD | GILEAD SCIENCES INC | 14.07 | 135.48B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.08 | 52.99B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.91B | ||
| ARGX | ARGENX SE - ADR | 101.67 | 35.70B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.19B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.3 | 26.59B | ||
| NTRA | NATERA INC | N/A | 21.94B | ||
| BIIB | BIOGEN INC | 8.29 | 19.22B | ||
| UTHR | UNITED THERAPEUTICS CORP | 12.99 | 14.68B |
Related stock screener links
About AMAM
Company Profile
Ambrx Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in La Jolla, California and currently employs 66 full-time employees. The company went IPO on 2021-06-18. Ambrx Biopharma Inc. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. The company is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its ADC targeting Human epidermal growth factor receptor 2 (HER2). The company uses genetic code technology platform to discover and develop engineered precision biologics. Its genetic code technology platform allows to incorporate, in a site-specific manner, synthetic amino acids (SAA), into proteins within living cells. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as modified cytokines and bispecific antibodies, and others.
Company Info
NEW AMBRX BIOPHARMA INC
10975 North Torrey Pines Road
La Jolla CALIFORNIA US
CEO: Feng Tian
Employees: 66
Phone: 18588752400
NEW AMBRX BIOPHARMA INC / AMAM FAQ
What is the stock price of NEW AMBRX BIOPHARMA INC today?
The current stock price of AMAM is 28 USD. The price increased by 0.07% in the last trading session.
What is the ticker symbol for NEW AMBRX BIOPHARMA INC stock?
The exchange symbol of NEW AMBRX BIOPHARMA INC is AMAM and it is listed on the Nasdaq exchange.
On which exchange is AMAM stock listed?
AMAM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEW AMBRX BIOPHARMA INC stock?
14 analysts have analysed AMAM and the average price target is 29.07 USD. This implies a price increase of 3.82% is expected in the next year compared to the current price of 28. Check the NEW AMBRX BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEW AMBRX BIOPHARMA INC worth?
NEW AMBRX BIOPHARMA INC (AMAM) has a market capitalization of 12.42B USD. This makes AMAM a Large Cap stock.
How many employees does NEW AMBRX BIOPHARMA INC have?
NEW AMBRX BIOPHARMA INC (AMAM) currently has 66 employees.
What are the support and resistance levels for NEW AMBRX BIOPHARMA INC (AMAM) stock?
NEW AMBRX BIOPHARMA INC (AMAM) has a support level at 27.95 and a resistance level at 28.01. Check the full technical report for a detailed analysis of AMAM support and resistance levels.
Is NEW AMBRX BIOPHARMA INC (AMAM) expected to grow?
The Revenue of NEW AMBRX BIOPHARMA INC (AMAM) is expected to decline by -57.14% in the next year. Check the estimates tab for more information on the AMAM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NEW AMBRX BIOPHARMA INC (AMAM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AMAM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AMAM, evaluating the profitability, health, valuation and growth aspects
- NEW AMBRX BIOPHARMA INC (AMAM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEW AMBRX BIOPHARMA INC (AMAM) Sales and EPS estimates to see what analysts future expectations are.
- NEW AMBRX BIOPHARMA INC (AMAM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEW AMBRX BIOPHARMA INC (AMAM) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEW AMBRX BIOPHARMA INC (AMAM) Stock Chart to make your own analysis
- NEW AMBRX BIOPHARMA INC (AMAM) Latest news and press-releases to stay up to date.
Does NEW AMBRX BIOPHARMA INC (AMAM) stock pay dividends?
AMAM does not pay a dividend.
When does NEW AMBRX BIOPHARMA INC (AMAM) report earnings?
NEW AMBRX BIOPHARMA INC (AMAM) will report earnings on 2024-03-26.
What is the Price/Earnings (PE) ratio of NEW AMBRX BIOPHARMA INC (AMAM)?
NEW AMBRX BIOPHARMA INC (AMAM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.57).
AMAM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AMAM. When comparing the yearly performance of all stocks, AMAM is one of the better performing stocks in the market, outperforming 98.51% of all stocks.
AMAM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to AMAM. While AMAM has a great health rating, there are worries on its profitability.
AMAM Financial Highlights
Over the last trailing twelve months AMAM reported a non-GAAP Earnings per Share(EPS) of -0.57. The EPS decreased by -16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.43% | ||
| ROE | -34.09% | ||
| Debt/Equity | 0 |
AMAM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to AMAM. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -159.66% and a revenue growth -57.14% for AMAM